Skip to content

Evaluation of Investigational Daily Disposable Multifocal Contact Lenses Produced With Different Manufacturing Processes in Myopes

Evaluation of Investigational Daily Disposable Multifocal Contact Lenses Produced With Different Manufacturing Processes in Myopes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04889625
Enrollment
81
Registered
2021-05-17
Start date
2021-05-21
Completion date
2021-07-21
Last updated
2022-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Visual Acuity

Brief summary

This is a single-masked, 2×3 crossover, randomized controlled, dispensing clinical trial to evaluate the visual performance (logMAR) and subjective vision responses of the Test Lens.

Interventions

Sponsors

Johnson & Johnson Vision Care, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Potential subjects must satisfy all the following criteria to be enrolled in the study: 1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. 2. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol. 3. The subject must be at least 40 years of age and not greater than 70 years of age at the time of consent. 4. Subjects must own a wearable pair of spectacles if required for their distance vision. 5. The subject must be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 6 hours per wear day, for 1 month or more duration). 6. The subject must either already be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.) or, if not respond positively to at least one symptom on the Presbyopic Symptoms Questionnaire (Appendix E). 7. The subject's distance spherical equivalent refraction must be in the range of -1.25 D to -3.75 D in each eye. 8. The subject's refractive cylinder must be ≤0.75 D in each eye. 9. The subject's ADD power must be in the range of +0.75 D to +2.50 D. 10. The subject must have distance best corrected visual acuity of 20/20-3 or better in each eye.

Exclusion criteria

* Potential subjects who meet any of the following criteria will be excluded from participating in the study: 1. Currently pregnant or lactating. 2. Any active or ongoing ocular or systemic allergies that may interfere with contact lens wear. 3. Any active or ongoing systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis). 4. Any previous, or planned, ocular or intraocular surgery (e.g. radial keratotomy, PRK, LASIK, lid procedures, cataract surgery, retinal surgery, etc.). 5. A history of amblyopia, strabismus or binocular vision abnormality. 6. Use of any of the following medications within 1 week prior to enrollment: oral retinoid, oral tetracyclines, anticholinergics, oral phenothiazines, oral/inhaled corticosteroids. See section 9.1 for further examples. 7. Use of any ocular medication, with the exception of rewetting drops. 8. History of herpetic keratitis. 9. History of irregular cornea. 10. History of pathological dry eye. 11. Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment. 12. Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician). 13. Any known hypersensitivity or allergic reaction to non-preserved rewetting drop solutions or sodium fluorescein. 14. Clinically significant (Grade 3 or greater) corneal edema, corneal vascularization, corneal staining, tarsal abnormalities or bulbar injection, or any other corneal or ocular abnormalities which would contraindicate contact lens wear. 15. Any current ocular infection or inflammation. 16. Any current ocular abnormality that may interfere with contact lens wear.

Design outcomes

Primary

MeasureTime frameDescription
Visual Acuity1-Week Follow-upBinocular visual performance on logMAR (Logarithm of Minimal Angle of Resolution) scale was evaluated at distance (4 meters), intermediate (64 centimeters) and near (40 centimeters) under high luminance high contrast (HLHC) lighting condition using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. The room illuminance was required to be between 7.3 and 7.9 EV (394-597 lux). For Distance (4 meters), the acceptable range for the chart luminance was 10.5-10.7 EV (181-208 cd/m2). For Intermediate (64cm) and Near (40cm), the acceptable range for the chart luminance 10.8-11.1 EV (223-274 cd/m2). Letter-by-letter results calculated the visual performance score for each chart read. logMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of 20/20.

Secondary

MeasureTime frameDescription
Overall Vision1-Week Follow-upOverall vision scores were assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.

Countries

United States

Participant flow

Recruitment details

A total of 81 subjects were enrolled in this study. Of those enrolled, 78 were dispensed at least one study lens while, 3 subjects failed to meet all eligibility criteria. Of those enrolled, 68 completed the study while 10 subjects were discontinued from the study.

Participants by arm

ArmCount
Dispensed Subjects
All subjects dispensed a study lens.
78
Total78

Withdrawals & dropouts

PeriodReasonFG000FG001
Period 1Discontinued due to fitting guide error11
Period 1Subject did not meet eligibility criteria and was enrolled by error21
Period 1Subject out of window01
Period 1Wrong add power dispensed01
Period 2Incorrect lens dispensed10
Period 2Test article no longer available10
Period 2Wrong add power dispensed01

Baseline characteristics

CharacteristicDispensed Subjects
Age, Continuous49.4 years
STANDARD_DEVIATION 5.96
Race/Ethnicity, Customized
Asian
1 participants
Race/Ethnicity, Customized
Black or African American
16 participants
Race/Ethnicity, Customized
White
61 participants
Region of Enrollment
United States
78 Participants
Sex: Female, Male
Female
64 Participants
Sex: Female, Male
Male
14 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 740 / 75
other
Total, other adverse events
0 / 740 / 75
serious
Total, serious adverse events
0 / 740 / 75

Outcome results

Primary

Visual Acuity

Binocular visual performance on logMAR (Logarithm of Minimal Angle of Resolution) scale was evaluated at distance (4 meters), intermediate (64 centimeters) and near (40 centimeters) under high luminance high contrast (HLHC) lighting condition using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. The room illuminance was required to be between 7.3 and 7.9 EV (394-597 lux). For Distance (4 meters), the acceptable range for the chart luminance was 10.5-10.7 EV (181-208 cd/m2). For Intermediate (64cm) and Near (40cm), the acceptable range for the chart luminance 10.8-11.1 EV (223-274 cd/m2). Letter-by-letter results calculated the visual performance score for each chart read. logMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of 20/20.

Time frame: 1-Week Follow-up

Population: Subjects that completed all study visits without a major protocol deviation impacting a primary or secondary endpoint.

ArmMeasureGroupValue (MEAN)Dispersion
Senofilcon A (C3)Visual AcuityDistance (4m)-0.13 logMARStandard Deviation 0.097
Senofilcon A (C3)Visual AcuityIntermediate (64cm)-0.04 logMARStandard Deviation 0.105
Senofilcon A (C3)Visual AcuityNear (40cm)0.07 logMARStandard Deviation 0.134
Delefilcon AVisual AcuityDistance (4m)-0.13 logMARStandard Deviation 0.088
Delefilcon AVisual AcuityIntermediate (64cm)-0.01 logMARStandard Deviation 0.106
Delefilcon AVisual AcuityNear (40cm)0.09 logMARStandard Deviation 0.128
Comparison: Distance (4m)95% CI: [-0.017, 0.017]Mixed Model Analysis
Comparison: Intermediate (64cm)95% CI: [-0.051, -0.008]Mixed Model Analysis
Comparison: Near (40cm)95% CI: [-0.062, -0.011]Mixed Model Analysis
Secondary

Overall Vision

Overall vision scores were assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.

Time frame: 1-Week Follow-up

Population: Subjects that completed all study visits without a major protocol deviation impacting a primary or secondary endpoint.

ArmMeasureValue (MEAN)Dispersion
Senofilcon A (C3)Overall Vision59.11 units on a scaleStandard Deviation 20.266
Delefilcon AOverall Vision52.84 units on a scaleStandard Deviation 19.457
95% CI: [2, 10.5]Mixed Model Analysis

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026